interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Cyclobenzaprine Hydrochloride

Generic competition · all medicines · read 12 November 2026

Is there a generic of Cyclobenzaprine Hydrochloride, and who makes it?

Cyclobenzaprine Hydrochloride appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 15 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 6 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Cyclobenzaprine Hydrochloride3 dosage-form groups in the Orange Book
15generic makers listed
  1. Cyclobenzaprine Hydrochloride appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 15 generic makers listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came 6 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Four or more generic makers listed

Every brand product here is listed as discontinued. 12 generic makers with 33 generic products listed as marketed; the first generic approval is dated 3 May 1989.

1985199019952000200520102015202020252030012Actavis Laboratories Fl Inc, first approval 3 May 1989Aiping Pharmaceutical Inc, first approval 19 November 1991Tp Anda Holdings Llc, first approval 23 May 1995Jubilant Cadista Pharmaceuticals Inc, first approval 19 April 2006Prinston Pharmaceutical Inc, first approval 28 February 2007Chartwell Rx Sciences Llc, first approval 18 April 2008Aurobindo Pharma Ltd, first approval 26 September 2008Invagen Pharmaceuticals Inc, first approval 23 July 2010Kvk Tech Inc, first approval 28 February 2011Rubicon Research Ltd, first approval 31 May 2017Unichem Laboratories Ltd, first approval 5 July 2020Rising Pharma Holdings Inc, first approval 12 September 2024data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Actavis Laboratories Fl Inc3 May 19893
Aiping Pharmaceutical Inc19 November 19913
Tp Anda Holdings Llc23 May 19954
Jubilant Cadista Pharmaceuticals Inc19 April 20063
Prinston Pharmaceutical Inc28 February 20072
Chartwell Rx Sciences Llc18 April 20083
Aurobindo Pharma Ltd26 September 20082
Invagen Pharmaceuticals Inc23 July 20102
Kvk Tech Inc28 February 20112
Rubicon Research Ltd31 May 20173
Unichem Laboratories Ltd5 July 20203
Rising Pharma Holdings Inc12 September 20243

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Capsule, Extended Release, Oral

One to three generic makers listed

Brand listed as marketed: Amrix. 3 generic makers with 6 generic products listed as marketed; the first generic approval is dated 31 January 2013.

20052010201520202025203003brand 2007Twi Pharmaceuticals Inc, first approval 31 January 2013Macleods Pharmaceuticals Ltd, first approval 22 July 2024Novast Laboratories Ltd, first approval 27 August 2024data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Twi Pharmaceuticals Inc31 January 20132
Macleods Pharmaceuticals Ltd22 July 20242
Novast Laboratories Ltd27 August 20242

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Tablet, Sublingual

Brand listed, no generic listed as marketed

Brand listed as marketed: Tonmya. No generic is listed as marketed.

202020252030203501brand 2025data datePatent 10117936 listed to expire 14 March 2034Patent 10864175 listed to expire 14 March 2034Patent 9636408 listed to expire 14 March 2034Patent 9956188 listed to expire 14 March 2034Exclusivity NP to 15 August 2028
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 15 August 2028Exclusivity NP Tonmya
  • 14 March 2034Patent 10117936 drug product
  • 14 March 2034Patent 10864175 drug product
  • 14 March 2034Patent 9636408 drug product
  • 14 March 2034Patent 9956188 drug product

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.